SEARCH RESULTS FOR: "Tag: CLVS"
REFINE YOUR SEARCH:
RECENT
Last Month(1)
ARTICLES/BLOGS
2019(6)
2018(5)
2017(6)
2016(15)
2015(10)
CATEGORIES
Analyst Downgrades(2)
Analyst Update(7)
Analyst Upgrades(4)
Buzz Stocks(6)
By the Numbers(1)
Earnings Preview(1)
Ezines(1)
General(2)
Intraday Option Activity(7)
Market Recap(1)
Midday Market Check(2)
Opening View(5)
Quantitative Analysis(1)
Stock Market News(5)
Stocks On the Move(7)
Technical Analysis(1)
Unusual Trading Activity(1)

9/24/2019 2:08 PM
SVB Leerink downgraded Clovis Oncology Inc (NASDAQ:CLVS) stock to "market perform" from "outperform," and slashed its price target by $12 to $10. The analyst in coverage called CLVS' licensing deal w...
5/29/2019 12:56 PM
This morning, Goldman Sachs weighed in on two pharma stocks, downgrading Clovis Oncology Inc (NASDAQ:CLVS) and Esperion Therapeutics Inc (NASDAQ:ESPR) to "sell." Regarding the former, Goldman believes...
4/15/2019 12:36 PM
Clovis Oncology Inc (NASDAQ:CLVS) late Friday said it was discontinuing a mid-stage trial of its lead cancer drug, rucaparib, in bladder cancer patients following the recommendation of an independent ...
3/4/2019 9:30 AM
The shares of Clovis Oncology Inc (NASDAQ:CLVS) are up 1.3% in electronic trading, on news the pharmaceutical firm's ovarian cancer treatment, rucaparib, is now available in Germany for women with re...
1/8/2019 12:12 PM
Yesterday, Clovis Oncology Inc (NASDAQ:CLVS) surged more than 18%, after better-than-expected sales numbers for its cancer drug Rubraca, as well as a bull note from Leerink. However, the good times f...

Welcome to Schaeffer's Investment Research! We are a privately held provider of stock and options trading recommendations, options education, and market commentary, headquartered in Cincinnati, Ohio. Founded in 1981 by industry pioneer Bernie Schaeffer, we've since become a trusted source of research and analysis for individual investors and major financial media outlets alike.







Partner Center